Intellia Therapeutics (NTLA) Prices 5.48M Share Common Offering at $18.25/Sh

Pre-Open Stock Movers 06/02: (MGI) (WU) (SWBI) Higher; (PUMP) (INVH) (GH) Lower (more...)

June 2, 2020 9:28 AM EDT

Today's Pre-Open Stock Movers:

MoneyGram (NASDAQ: MGI) 43.6% HIGHER; Western Union (NYSE: WU) is seeking to acquire MoneyGram (NASDAQ: MGI) and recently made a takeover offer, according to Bloomberg, citing a person familiar with the matter.

Western Union (NYSE: WU) 15% HIGHER; is seeking to acquire MoneyGram (NASDAQ: MGI) and recently made a takeover offer, according to Bloomberg,... More

UPDATE: Intellia Therapeutics (NTLA) PT Raised to $21 at Credit Suisse

June 2, 2020 6:03 AM EDT

(Updated - June 2, 2020 7:29 AM EDT)

(updated to fix firm name)

Credit Suisse analyst Martin Auster raised its price target on Intellia Therapeutics (NASDAQ: NTLA) to $21.00 (from $19.00) while maintaining a Neutral rating.

... More

After-Hours Stock Movers 6/1: (MGI) (KLDO) (XGN) HIGHER; (PUMP) (INVH) (GH) LOWER (more...)

June 1, 2020 5:30 PM EDT

Today's After-Hours Stock Movers:

MoneyGram (NASDAQ: MGI) 31% HIGHER; Western Union (NYSE: WU) is seeking to acquire MoneyGram (NASDAQ: MGI) and recently made a takeover offer, according to Bloomberg, citing a person familiar with the matter.

ProPetro Holding (NYSE: PUMP) 9% LOWER; reported Q1 EPS of ($0.08), may not compare the analyst estimate of $0.20. Revenue for the quarter came in at $395.1 million versus the consensus estimate of $390.56... More

Intellia Therapeutics (NTLA) Announces $75M Proposed Public Offering of Common Stock

June 1, 2020 4:00 PM EDT

(Updated - June 1, 2020 4:01 PM EDT)

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that it has commenced an underwritten public... More

Intellia Therapeutics (NTLA) PT Raised to $20 at Wedbush, Following Business Update

June 1, 2020 12:53 PM EDT

Wedbush analyst David Nierengarten raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $20.00 (from $16.00) while maintaining a Neutral rating.

... More

Pre-Open Movers 06/01: (PTI) (COTY) (AAXN) Higher; (NVUS) (PFE) (GILD) Lower (more...)

June 1, 2020 9:27 AM EDT

Today's Pre-Open Movers

Novus Therapeutics, Inc. (NASDAQ: NVUS) 59% LOWER; announced topline results from the companys exploratory phase 2a clinical trial of OP0201 in acute otitis media (study C-006). Study C-006 was a phase 2a, single center, double-blind, randomized, placebo-controlled, parallel group clinical trial to assess the safety, tolerability, and efficacy of 20 mg per day intranasal OP0201 as an adjunct therapy to oral antibiotic in the treatment of acute otitis media in infants and children 6 to 24 months of age. Subjects were treated twice-daily for 10 days and followed up to one month.... More

Regeneron (REGN) and Intellia Therapeutics (NTLA) Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

June 1, 2020 7:04 AM EDT

Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilitiesRegeneron gains rights to develop products for additional in vivo targets and new rights for ex vivo product developmentIntellia receives $100 million through upfront cash and equity investment

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced an expansion of their... More